ClinicalTrials.gg
CompletedNCT02152371AWARD-9Updated Sep 25, 2019Results posted

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

A Phase 3 interventional study of Dulaglutide and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
21st of 54
300 · median 159
Started
2014
the only one that year
Phase 3
22 of 54
1 open now
Registered
29th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is the only one that started in 2014, is one of 22 in phase 3, and was the 29th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes (based on the World Health Organization's [WHO] diagnostic criteria)
  • Have been treated with basal insulin glargine once daily with or without metformin for at least 3 months prior to screening
  • Doses of once daily insulin glargine and metformin (if taken) must be stable during the 3-month period prior to screening. Doses of metformin are considered stable if all prescribed doses during this period are in the range between the minimum required dose (≥1500 mg/day) and the maximum approved dose per the locally-approved label
  • Have an value ≥7.0% and ≤10.5% as assessed by the central laboratory at screening
  • Require further insulin glargine dose increase at week 3 per the treat-to-target (TTT) algorithm based on the SMPG data collected during the prior week
  • Have stable weight (±5%) ≥3 months prior to screening
  • Have (BMI) ≤45 kilograms per square meter (kg/m\^2) at screening
  • Are able and willing to administer once weekly randomized therapy
  • Are females of who must:

    • Test negative for pregnancy at screening, based on a serum pregnancy test
    • Agree to use a reliable method of
    • Not be breastfeeding

Exclusion criteria

Exclusion Criteria:

  • Have been treated with ANY other antihyperglycemia regimen, other than basal insulin glargine once daily with or without metformin, within the 3 months prior to screening or between screening and week 3
  • Have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma
  • Have a history of hypoglycemia unawareness within the 6 months prior to screening
  • Have been treated with drugs that promote weight loss within the 3 months prior to screening or between screening and week 3
  • Are receiving chronic (>14 days) systemic therapy or have received such therapy within the 4 weeks prior to screening or between screening and week 3
  • Have had any of the following cardiovascular conditions within the 2 months prior to screening: acute myocardial infarction (MI), (NYHA) Class III or Class IV heart failure, or cerebrovascular accident (stroke)
  • Have a known gastric emptying abnormality or have undergone gastric bypass surgery or restrictive bariatric surgery
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or (ALT) level >2.5 times the upper limit of the reference range, as determined by the central laboratory
  • Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis within the 3 months prior to screening
  • Have an estimated (eGFR) \<30 milliliters/minute/1.73 square meter (mL/min/m\^2), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as determined by the central laboratory; for participants on metformin, have renal disease or renal dysfunction (for example, a serum creatinine ≥1.5 mg/deciliter [dL] [male] or ≥1.4 mg/dL [female] or eGFR [CKD-EPI] \<60 mL/min/1.73 m\^2)
  • Have evidence of a significant, uncontrolled endocrine abnormality
  • Have any self or family history of type 2A or type 2B multiple endocrine neoplasia (MEN 2A or 2B) in the absence of known C-cell hyperplasia
  • Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)
  • Have serum calcitonin ≥20 picograms/mL, as determined by the central laboratory
  • Have evidence of a significant, active abnormality
  • Have any other condition not listed in this section that is a for use of insulin glargine, or, for participants using metformin, have a condition that is a contraindication for the use of metformin and would require metformin discontinuation per label
  • Have a history of transplanted organ
  • Have a history of active or untreated , or are in remission from a clinically significant malignancy during the 5 years prior to screening
  • Have a history of any other condition which, in the opinion of the investigator, may preclude the participants from following and completing the protocol
  • Have any hematologic condition that may interfere with measurement (eg, hemolytic anemias, sickle-cell disease)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Dulaglutide + Insulin Glargine

    1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.

    Drug: Dulaglutide · Drug: Insulin Glargine · Drug: Metformin

  • Placebo comparator
    Placebo + Insulin Glargine

    Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.

    Drug: Placebo · Drug: Insulin Glargine · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least-squares (LS) mean and standard error (SE) changes from baseline in HbA1c at 28 weeks were measured using mixed model regression and restricted maximum likelihood (REML) with treatment, pooled country, visit, and treatment-by -visit interaction as fixed effects, baseline as covariate, and participant as a random effect.

    Time frame: Baseline, 28 Weeks

Secondary outcomes

  1. Change From Baseline to 28 Weeks in Fasting Serum Glucose (FSG)

    FSG is a test to determine glucose levels after an overnight fast. LS means FSG change from baseline to primary endpoint at week 28 was calculated using a mixed effects model for repeated measures (MMRM) analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline FSG as covariate.

    Time frame: Baseline, 28 Weeks

  2. Change From Baseline to 28 Weeks in 7-Point Self Monitored Plasma Glucose (SMPG)

    The LS means of the 7-point SMPG change from baseline to primary endpoint at week 28 was measured using a MMRM analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline SMPG as covariate.

    Time frame: Baseline, 28 Weeks

  3. Change From Baseline to 28 Weeks in Body Weight

    LS means of the body weight change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline body weight as covariate, via a MMRM analysis.

    Time frame: Baseline, 28 Weeks

  4. Change From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose

    Least Square (LS) Means of the insulin dose change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline insulin dose as covariate, via a MMRM analysis.

    Time frame: Baseline, 28 Weeks

  5. Number of Participants With Investigator Reported and Adjudicated Cardiovascular Events

    Cardiovascular (CV) adverse events (AEs) were adjudicated by an independent committee of physicians with cardiology expertise external to the sponsor. Deaths occurring during the study treatment period and nonfatal CV AEs were to be adjudicated. Nonfatal CV events that were to be adjudicated were myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI); and cerebrovascular events, including cerebrovascular accident (CVA/stroke), and transient ischemic attack (TIA).

    Time frame: Baseline through 28 Weeks

  6. Percentage of Participants With Self-Reported Events of Hypoglycemia

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The percentage of participants with self-reported hypoglycemic events is presented.

    Time frame: Baseline through 28 Weeks

  7. Percentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia

    Time frame: Baseline through 28 Weeks

  8. Number of Participants With Adjudicated Acute Pancreatitis Events

    The number of cases of acute pancreatitis confirmed by adjudication. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline through 28 Weeks

  9. Number of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia)

    Time frame: Baseline through 28 Weeks

  10. Number of Participants With Dulaglutide Anti-Drug Antibodies

    Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 12 and 28. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

    Time frame: Baseline, Week 12 and Week 28

  11. Percentage of Participants Achieving HbA1c Targets of <7.0% or ≤6.5%

    Percentage of participants who achieved HbA1c levels of \<7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.

    Time frame: 28 Weeks

  12. Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)

    Percentage of participants who achieved a target HbA1c target of \<7%, without weight gain and without documented symptomatic hypoglycemia at 28 weeks were analyzed using regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.

    Time frame: 28 Weeks

  13. Percentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)

    Percentage of participants achieving target HbA1c of \<7.0% at 28 weeks without documented symptomatic hypoglycemia are presented. Documented symptomatic hypoglycemia is defined as any time a participant experienced symptoms and or signs associated with hypoglycemia and had a plasma glucose of \<=70 mg/dL.

    Time frame: 28 Weeks

  14. Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg)

    Time frame: 28 Weeks

  15. Rate of Hypoglycemic Events up to 28 Weeks

    The rate of total hypoglycemic events any type per 30 days is presented. The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days.

    Time frame: Baseline through 28 Weeks

07

Results

Posted Dec 7, 2016

Participant flow

Participant flow — Overall Study
MilestoneDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Started150150
Received at least 1 dose of study drug.150150
Completed138134
Not completed1216
Withdrew: Adverse event62
Withdrew: Withdrawal by subject37
Withdrew: Protocol violation23
Withdrew: Lost to follow-up10
Withdrew: Lack of efficacy01
Withdrew: Physician decision02
Withdrew: Reason not given01

Outcome measures

PrimaryChange From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least-squares (LS) mean and standard error (SE) changes from baseline in HbA1c at 28 weeks were measured using mixed model regression and restricted maximum likelihood (REML) with treatment, pooled country, visit, and treatment-by -visit interaction as fixed effects, baseline as covariate, and participant as a random effect.

Time frame:
Baseline, 28 Weeks
Reported as:
Least squares mean · percentage of change
Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)
percentage of changeDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c)-1.44 ± 0.09-0.67 ± 0.09
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Model for Repeated Measures (MMRM) · p = <.001 · Ls means diff: -0.77 · 95% CI -0.97 to -0.56
SecondaryChange From Baseline to 28 Weeks in Fasting Serum Glucose (FSG)

FSG is a test to determine glucose levels after an overnight fast. LS means FSG change from baseline to primary endpoint at week 28 was calculated using a mixed effects model for repeated measures (MMRM) analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline FSG as covariate.

Time frame:
Baseline, 28 Weeks
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline to 28 Weeks in Fasting Serum Glucose (FSG)
milligram per deciliter (mg/dL)Dulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Change From Baseline to 28 Weeks in Fasting Serum Glucose (FSG)-44.63 ± 4.16-27.90 ± 4.08
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = <.001 · Ls mean diff: -16.73 · 95% CI -26.02 to -7.44
SecondaryChange From Baseline to 28 Weeks in 7-Point Self Monitored Plasma Glucose (SMPG)

The LS means of the 7-point SMPG change from baseline to primary endpoint at week 28 was measured using a MMRM analysis adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline SMPG as covariate.

Time frame:
Baseline, 28 Weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline to 28 Weeks in 7-Point Self Monitored Plasma Glucose (SMPG)
mg/dLDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Pre-Morning Meal (n=133,129)-44.03 ± 2.71-35.97 ± 2.64
Morning Meal 2-Hour Postprandial (n=123,119)-64.16 ± 4.31-46.97 ± 4.27
Pre-Midday Meal (n=133,127)-40.89 ± 3.72-25.34 ± 3.62
Midday Meal 2-Hour Post Prandial (n=123,117)-51.13 ± 4.40-32.98 ± 4.33
Pre-Evening Meal (n=133,129)-43.68 ± 4.21-28.71 ± 4.07
Evening Meal 2-Hour Postprandial (n=126,122)-48.63 ± 5.22-27.35 ± 5.16
3:00 AM (Morning) (n=124,117)-39.77 ± 4.27-20.30 ± 4.23
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = .007 · Ls mean diff: -8.06 · 95% CI -13.87 to -2.25
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = <.001 · Ls mean diff: -17.18 · 95% CI -25.96 to -8.40
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = <.001 · Ls mean diff: -15.55 · 95% CI -23.58 to -7.52
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = <.001 · Ls mean diff: -18.15 · 95% CI -27.18 to -9.12
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = .001 · Ls mean diff: -14.96 · 95% CI -23.93 to -5.99
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = <.001 · Ls mean diff: -21.28 · 95% CI -32.46 to -10.10
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = <.001 · Ls mean diff: -19.48 · 95% CI -28.77 to -10.18
SecondaryChange From Baseline to 28 Weeks in Body Weight

LS means of the body weight change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline body weight as covariate, via a MMRM analysis.

Time frame:
Baseline, 28 Weeks
Reported as:
Least squares mean · kilogram(kg)
Change From Baseline to 28 Weeks in Body Weight
kilogram(kg)Dulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Change From Baseline to 28 Weeks in Body Weight-1.91 ± 0.300.50 ± 0.30
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Mixed Models Analysis · p = <.001 · Ls means difference: -2.41 · 95% CI -3.19 to -1.64
SecondaryChange From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose

Least Square (LS) Means of the insulin dose change from baseline to primary endpoint at week 28 was adjusted by treatment, country, metformin use, week, treatment-by-week interaction, and baseline insulin dose as covariate, via a MMRM analysis.

Time frame:
Baseline, 28 Weeks
Reported as:
Least squares mean · units (u)
Change From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose
units (u)Dulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Change From Baseline to 28 Weeks in Daily Mean Insulin Glargine Dose12.75 ± 2.2725.94 ± 2.30
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · MMRM · p = <.001 · Ls means diff: -13.19 · 95% CI -19.55 to -6.84
SecondaryNumber of Participants With Investigator Reported and Adjudicated Cardiovascular Events

Cardiovascular (CV) adverse events (AEs) were adjudicated by an independent committee of physicians with cardiology expertise external to the sponsor. Deaths occurring during the study treatment period and nonfatal CV AEs were to be adjudicated. Nonfatal CV events that were to be adjudicated were myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI); and cerebrovascular events, including cerebrovascular accident (CVA/stroke), and transient ischemic attack (TIA).

Time frame:
Baseline through 28 Weeks
Reported as:
Number · participants
Number of Participants With Investigator Reported and Adjudicated Cardiovascular Events
participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Number of Participants With Investigator Reported and Adjudicated Cardiovascular Events31
SecondaryPercentage of Participants With Self-Reported Events of Hypoglycemia

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The percentage of participants with self-reported hypoglycemic events is presented.

Time frame:
Baseline through 28 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Self-Reported Events of Hypoglycemia
percentage of participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Symptomatic35.330.0
Asymptomatic42.739.3
Severe0.70.0
Nocturnal28.028.7
Probable Symptomatic2.72.0
SecondaryPercentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia
Time frame:
Baseline through 28 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia
percentage of participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Percentage of Participants Discontinuing the Study Due to Severe, Persistent Hyperglycemia00
SecondaryNumber of Participants With Adjudicated Acute Pancreatitis Events

The number of cases of acute pancreatitis confirmed by adjudication. A summary of serious and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline through 28 Weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Acute Pancreatitis Events
participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Number of Participants With Adjudicated Acute Pancreatitis Events00
SecondaryNumber of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia)
Time frame:
Baseline through 28 Weeks
Reported as:
Number · participants
Number of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia)
participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Number of Participants With Thyroid Tumors/Neoplasms (Including C-Cell Hyperplasia)10
SecondaryNumber of Participants With Dulaglutide Anti-Drug Antibodies

Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 12 and 28. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

Time frame:
Baseline, Week 12 and Week 28
Reported as:
Number · participants
Number of Participants With Dulaglutide Anti-Drug Antibodies
participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Number of Participants With Dulaglutide Anti-Drug Antibodies02
SecondaryPercentage of Participants Achieving HbA1c Targets of <7.0% or ≤6.5%

Percentage of participants who achieved HbA1c levels of \<7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.

Time frame:
28 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c Targets of <7.0% or ≤6.5%
percentage of participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
HbA1c <= 6.550.716.7
HbA1c < 7.069.335.3
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Regression, Logistic · p = <.001 · Odds ratio (or): 6.66 · 95% CI 3.70 to 12.00
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Regression, Logistic · p = <.001 · Odds ratio, log: 5.71 · 95% CI 3.35 to 9.73
SecondaryPercentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)

Percentage of participants who achieved a target HbA1c target of \<7%, without weight gain and without documented symptomatic hypoglycemia at 28 weeks were analyzed using regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.

Time frame:
28 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)
percentage of participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 Kilograms [kg]) at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)40.716.7
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Regression, Logistic · p = <.001 · Odds ratio (or): 4.17 · 95% CI 2.32 to 7.47
SecondaryPercentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)

Percentage of participants achieving target HbA1c of \<7.0% at 28 weeks without documented symptomatic hypoglycemia are presented. Documented symptomatic hypoglycemia is defined as any time a participant experienced symptoms and or signs associated with hypoglycemia and had a plasma glucose of \<=70 mg/dL.

Time frame:
28 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)
percentage of participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Percentage of Participants Achieving HbA1c Target of <7.0% at 28 Weeks and Without Documented Symptomatic Hypoglycemia During the Maintenance Period (Weeks 12-28)52.028.0
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Regression, Logistic · p = <.001 · Odds ratio (or): 3.61 · 95% CI 2.09 to 6.23
SecondaryPercentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg)
Time frame:
28 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg)
percentage of participantsDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Percentage of Participants Achieving HbA1c Target of <7.0% and Without Weight Gain (<0.1 kg)52.720.0
Statistical analysis
  • Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine · Regression, Logistic · p = <.001 · Odds ratio (or): 5.60 · 95% CI 3.26 to 9.62
SecondaryRate of Hypoglycemic Events up to 28 Weeks

The rate of total hypoglycemic events any type per 30 days is presented. The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days.

Time frame:
Baseline through 28 Weeks
Reported as:
Mean · rate of hypoglycemic events per 30 days
Rate of Hypoglycemic Events up to 28 Weeks
rate of hypoglycemic events per 30 daysDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
Rate of Hypoglycemic Events up to 28 Weeks0.63 ± 1.240.70 ± 1.32

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dulaglutide + Insulin Glargine—9/150 (6%)51/150 (34%)
Placebo + Insulin Glargine—7/150 (4.7%)29/150 (19.3%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
BradycardiaCardiac disorders2/1500/150
Transient ischaemic attackNervous system disorders2/1500/150
Angina unstableCardiac disorders1/1501/150
Atrial fibrillationCardiac disorders1/1500/150
Coronary artery diseaseCardiac disorders1/1500/150
Myocardial infarctionCardiac disorders1/1500/150
Non-cardiac chest painGeneral disorders0/1501/150
Granulomatous liver diseaseHepatobiliary disorders1/1500/150
GastroenteritisInfections and infestations1/1500/150
Viral infectionInfections and infestations0/1501/150
Most frequent other events
Most frequent other events
EventDulaglutide + Insulin GlarginePlacebo + Insulin Glargine
NauseaGastrointestinal disorders18/1502/150
DiarrhoeaGastrointestinal disorders17/1506/150
NasopharyngitisInfections and infestations6/15014/150
Upper respiratory tract infectionInfections and infestations11/15010/150
Decreased appetiteMetabolism and nutrition disorders10/1500/150
DyspepsiaGastrointestinal disorders9/1500/150
VomitingGastrointestinal disorders9/1500/150

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Dulaglutide + Insulin GlarginePlacebo + Insulin GlargineTotal
Mean60.2 ± 9.4760.6 ± 10.0760.4 ± 9.76
Sex: Female, Male
Sex: Female, Male(Participants)Dulaglutide + Insulin GlarginePlacebo + Insulin GlargineTotal
Female6562127
Male8588173
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dulaglutide + Insulin GlarginePlacebo + Insulin GlargineTotal
Hispanic or Latino262551
Not Hispanic or Latino104104208
Unknown or Not Reported202141
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dulaglutide + Insulin GlarginePlacebo + Insulin GlargineTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander123
Black or African American5611
White143138281
More than one race134
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Dulaglutide + Insulin GlarginePlacebo + Insulin GlargineTotal
Czech Republic252752
Puerto Rico121628
Hungary373572
United States322961
Italy131528
United Kingdom224
Spain292655
Mean Insulin Glargine Dose
Mean Insulin Glargine Dose(Units (U))Dulaglutide + Insulin GlarginePlacebo + Insulin GlargineTotal
Mean40.71 ± 23.1236.59 ± 21.4638.65 ± 22.37
Metformin Use at Baseline
Metformin Use at Baseline(participants)Dulaglutide + Insulin GlarginePlacebo + Insulin GlargineTotal
Treated with Metformin134131265
Not Treated with Metformin161935
08

Study locations

40 sites
  • Valley Endocrine, Fresno
    Fresno, California 93720, United States
  • Mills-Peninsula Diabetes Research Insitute
    San Mateo, California 94401, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Northwest Endo Diabetes Research, LLC
    Arlington Heights, Illinois 60005, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • Kentucky Diabetes Endocrinology Center
    Lexington, Kentucky 40503, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • SHS Clinical Research Group
    Toms River, New Jersey 08753, United States
  • Bland Clinic, PA
    Greensboro, North Carolina 27401, United States
  • PMG Research of Knoxville
    Knoxville, Tennessee 37912, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Polyclinic
    Seattle, Washington 98104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beroun, 26601, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brandys Nad Labem-Stara Bolesl, 25001, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ceske Budejovice, 370 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krnov, 79401, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 149 00, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1139, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Debrecen, 4043, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagykanizsa, 8800, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monza, 20900, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Olbia, 07026, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pisa, 56126, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00128, Italy
  • Centro de Endocrinologia y Nutricion del Turabo
    Caguas, 00726, Puerto Rico
  • Manati Center for Clinical Research Inc
    Manati, 00674, Puerto Rico
  • Ponce School of Medicine CAIMED Center
    Ponce, 00716, Puerto Rico
  • Endocrine Lipid Diabetes Research Institute
    Ponce, 00717-2075, Puerto Rico
  • GCM Medical Group PSC
    San Juan, 00909, Puerto Rico
  • American Telemedicine Center
    San Juan, 00917-3104, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alzira, 46600, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cadiz, 11540, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28223, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Teruel, 44002, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mortimer, Berks RG7 3SQ, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leicester, Leicestershire LE5 4PW, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guildford, Surrey GU2 7XX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Swansea, Wales SA6 6NL, United Kingdom
09

References and documents

Publications

  • Pantalone KM, Patel H, Yu M, Fernandez Lando L. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Diabetes Obes Metab. 2018 Jun;20(6):1461-1469. doi: 10.1111/dom.13252. Epub 2018 Mar 23. PubMed 29430801 ↗
  • Yu M, Brunt KV, Milicevic Z, Varnado O, Boye KS. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clin Ther. 2017 Nov;39(11):2284-2295. doi: 10.1016/j.clinthera.2017.10.002. Epub 2017 Oct 27. PubMed 29110972 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2014
First posted
Jun 2, 2014
Start
May 2014
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Dec 7, 2016
Last update
Sep 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02152371
Responsible party
Sponsor
First posted
Jun 2, 2014
Start date
May 2014
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Dec 7, 2016
Last update
Sep 25, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion